D
Sarepta Therapeutics, Inc. SRPT
$18.03 $0.633.59% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$17.40
Volume
152,453
Avg Vol (90D)
4,003,052
Market Cap
$1.82B
Dividend & Yield
--
52-Week Range
$10.42 - $111.21
P/E (TTM)
--
EPS (TTM)
-$2.90
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
8/12/2025 - MarketBeat
ING Groep NV Has $4.64 Million Stock Holdings in Sarepta Therapeutics, Inc. $SRPT
2/13/2026 - MarketBeat
Principal Financial Group Inc. Acquires 244,181 Shares of Sarepta Therapeutics, Inc. $SRPT
2/13/2026 - MarketBeat
Has Sarepta Therapeutics (SRPT) Fallen Too Far After Its Sharp Multi Year Share Price Slide?
2/11/2026 - Simply Wall St
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
2/11/2026 - Business Wire
New York State Common Retirement Fund Has $703,000 Position in Sarepta Therapeutics, Inc. $SRPT
2/11/2026 - MarketBeat
Sarepta Therapeutics (SRPT, $18.49) RSI Indicator left the oversold zone on February 06, 2026
2/7/2026 - Tickeron - Stocks
Sarepta Therapeutics (SRPT, $17.03) price may climb as it broke lower Bollinger Band on Feb 05, 2026
2/6/2026 - Tickeron - Technical Analysis
Sarepta Therapeutics (SRPT, $17.03) RSI Indicator left the oversold zone on February 05, 2026
2/6/2026 - Tickeron - Technical Analysis
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL), Sable Offshore Corp. (SOC), Sarepta Therapeutics, Inc. (SRPT), and Semler Scientific, Inc. (SMLR)
2/5/2026 - Globe Newswire
Is Sarepta (SRPT) Quietly Redefining Its Rare Disease Strategy With a Huntington's Trial Bet?
2/5/2026 - Simply Wall St
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Hold" by Brokerages
2/5/2026 - MarketBeat
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntingtons Disease
2/4/2026 - Business Wire
Assessing Sarepta Therapeutics (SRPT) Valuation After Positive Three Year EMBARK Data For Elevidys
2/4/2026 - Simply Wall St
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Danaher (DHR) and BridgeBio Pharma (BBIO)
2/2/2026 - TipRanks Financial Blog
Sarepta's Elevidys Data Reshapes Duchenne Risk Profile For Long-Term Investors
2/1/2026 - Simply Wall St
Y Intercept Hong Kong Ltd Lowers Position in Sarepta Therapeutics, Inc. $SRPT
1/31/2026 - MarketBeat
Sarepta Therapeutics (SRPT, $20.34) price exceeded its 50-day Moving Average on January 30, 2026
1/31/2026 - Tickeron - Stocks
Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags
1/31/2026 - MarketBeat
Commit To Purchase Sarepta Therapeutics At $15, Earn 22.2% Annualized Using Options
1/30/2026 - Stock Options Channel
How Sarepta's Long-Term ELEVIDYS Duchenne Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story
1/29/2026 - Simply Wall St
Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Barclays
1/28/2026 - MarketBeat
Sarepta Therapeutics (SRPT, $22.17) entered Uptrend as Momentum indicator ascends above 0 level on Jan 27, 2026
1/28/2026 - Tickeron - Stocks
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
1/27/2026 - Zacks Investment Research
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
6/18/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$2.41B
EBITDA (TTM)
-$36.28M
EBIT (TTM)
-$86.01M
Net Income (TTM)
-$271.51M
Balance Sheet
Total Assets (Q)
$3.49B
Total Debt (Q)
$1.26B
Total Liabilities (Q)
$2.17B
Book Value Per Share (Q)
$12.60
Cash Flow
Cash from Operations (TTM)
-$244.64M
Cash from Investing (TTM)
$737.55M
Cash from Financing (TTM)
-$80.15M
Net Change in Cash (TTM)
$412.77M
Filings
Filing Date
Thursday, November 6, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
0.84
7-Day Total Return
-8.64%
30-Day Total Return
-16.24%
60-Day Total Return
2.77%
90-Day Total Return
-22.51%
Year to Date Total Return
-15.42%
1-Year Total Return
-83.53%
2-Year Total Return
-85.49%
3-Year Total Return
-85.00%
5-Year Total Return
-80.17%
52-week Low
Jul 24, 2025 - $10.42
52-week High
Feb 14, 2025 - $111.21
Valuation
Market Cap
$1.82B - Small Cap
Enterprise Value
$2.23B
Price/Sales (TTM)
0.72
Price/Book (Q)
1.38
Dividends and Shares
Shares Outstanding
100.24M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.sarepta.com
Phone Number
617 274 4000
Address
215 First Street
Cambridge, MA 02142
Country
United States
Year Founded
1980
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic... more
NASDAQ 02/13/2026 9:56AM Eastern Quotes delayed